Company Profile
Coreline Soft Co., Ltd. is a South Korea-based developer of AI-powered medical imaging software, headquartered in Seoul, South Korea. Founded in 2012 by CEO Kim Jin-kook, the company operates as a publicly listed entity serving global radiology and screening markets with products deployed across 19 countries and cumulative use exceeding 2.5 million cases.
Core Products ＆ Technologies
AI Chest CT Screening
• AVIEW LCS Plus: 3-in-1 chest CT AI platform simultaneously analyzing lung cancer, COPD, and coronary artery calcification from a single low-dose scan
• AVIEW Lung Nodule CAD: FDA-cleared AI software detecting lung nodules with 34% increased sensitivity and 42% reduced false positives
• AVIEW COPD: Automated COPD analysis software quantifying emphysema, airway measurements, and lung lobe segmentation
• AVIEW Lung Texture: Fully automated quantitative analysis software for interstitial lung disease with 6-pattern fibrotic classification
• AVIEW CAC: Coronary artery calcium scoring system for cardiovascular risk assessment
AI Platform ＆ Workflow Infrastructure
• AVIEW HUB: Centralized operational platform launched in 2026 for multi-site screening workflows, second reading, consensus management, and longitudinal follow-up, designed for national reimbursement programs
• AVIEW 2.0: Upgraded AI imaging platform integrating enhanced security, UI/UX, and data extraction across the product lineup
• AVIEW CHEST: Combination device analyzing lung and cardiovascular diseases with a single CT scan
Market Position ＆ Certifications
Coreline Soft holds an emerging leadership position in the global chest CT AI software market, competing with VUNO Inc. and Lunit Inc. Key strengths include:
• 14 years of Korean AI medical imaging heritage
• Regulatory breadth: 9+ FDA 510(k) clearances covering multiple AI algorithms, CE marking, MFDS approval, Japan PMDA certification, Singapore HSA clearance, and HIPAA compliance
• Global deployment: 2.5 million+ cumulative cases across 19 countries; supply contracts with UK NHS, French National Cancer Institute, and German HANSE screening trial
• Clinical validation: AVIEW LCS Plus recognized in the European Journal of Cancer for first-reading performance; deployed at Charité Berlin, Heidelberg, and other leading institutions
• Pharma partnerships: Integration into Bayer's Calantic platform and Boehringer Ingelheim Taiwan's antifibrotic drug trial programs
Corporate Timeline
2012 — Founded in Seoul, South Korea, developing AI-based thoracic imaging solutions
2023 — Became a publicly listed company
2024 — Obtained Singapore HSA approvals for AVIEW product line; cumulative research publications reached 296
2025 — Secured multiple FDA 510(k) clearances including AVIEW CAC (December) and AVIEW Lung Nodule CAD (August); completed HIPAA certification
2026 — Ranked top 20 globally in FDA-approved AI medical devices (January); launched AVIEW HUB for Germany's reimbursed lung cancer screening rollout (April); AVIEW CAC received U.S. CMS HCPCS code G0680 (April); selected for Korean government R＆D project with KRW 2.2 billion support (May)
Target Markets ＆ Applications
• Lung Cancer Screening: AVIEW LCS Plus for early nodule detection, Lung-RADS classification, and follow-up comparison in national screening programs
• COPD Management: AVIEW COPD for quantitative emphysema analysis and airway measurement in pulmonary clinics
• Interstitial Lung Disease: AVIEW Lung Texture for fibrotic pattern quantification supporting antifibrotic drug trials
• Cardiovascular Risk Assessment: AVIEW CAC for coronary calcium scoring from routine chest CT
• Multi-Center Screening Operations: AVIEW HUB for structured reporting, independent second reading, and quality assurance in national reimbursement programs
Contact Information
Global Headquarters
Address: 12, Donggyo-ro 19-gil, Mapo-gu, Seoul 04001, South Korea
Telephone: +82 2 571 7321
Email: support@corelinesoft.com
Corporate Status
Entity Type: Publicly Listed Company (No Parent Company)
Stock: Publicly Listed Since 2023
Website: corelinesoft.com
